Cargando…
Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant
By vaccinating SARS-CoV-2 naïve individuals who have already received two doses of COVID-19 vaccines, we aimed to investigate whether a heterologous prime-boost strategy, using vaccines of different platforms as the booster dose, can enhance the immune response against SARS-CoV-2 virus variants. Par...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877145/ https://www.ncbi.nlm.nih.gov/pubmed/35214619 http://dx.doi.org/10.3390/vaccines10020160 |
_version_ | 1784658341501337600 |
---|---|
author | Khong, Ka-Wa Liu, Danlei Leung, Ka-Yi Lu, Lu Lam, Hoi-Yan Chen, Linlei Chan, Pui-Chun Lam, Ho-Ming Xie, Xiaochun Zhang, Ruiqi Fan, Yujing To, Kelvin Kai-Wang Chen, Honglin Yuen, Kwok-Yung Chan, Kwok-Hung Hung, Ivan Fan-Ngai |
author_facet | Khong, Ka-Wa Liu, Danlei Leung, Ka-Yi Lu, Lu Lam, Hoi-Yan Chen, Linlei Chan, Pui-Chun Lam, Ho-Ming Xie, Xiaochun Zhang, Ruiqi Fan, Yujing To, Kelvin Kai-Wang Chen, Honglin Yuen, Kwok-Yung Chan, Kwok-Hung Hung, Ivan Fan-Ngai |
author_sort | Khong, Ka-Wa |
collection | PubMed |
description | By vaccinating SARS-CoV-2 naïve individuals who have already received two doses of COVID-19 vaccines, we aimed to investigate whether a heterologous prime-boost strategy, using vaccines of different platforms as the booster dose, can enhance the immune response against SARS-CoV-2 virus variants. Participants were assigned into four groups, each receiving different combination of vaccinations: two doses of BNT162b2 followed by one dose of BNT162b2 booster (B-B-B); Combination of BNT162b2 (first dose) and CoronaVac (second dose) followed by one dose of BNT162b2 booster (B-C-B); two doses of CoronaVac followed by one dose of CoronaVac booster (C-C-C); two doses of CoronaVac followed by one dose of BNT162b2 booster (C-C-B). The neutralizing antibody in sera against the virus was determined with live virus microneutralization assay (vMN). The B-B-B group and C-C-B group demonstrated significantly higher immunogenicity against SARS-CoV-2 Wild type (WT), Beta variant (BV) and Delta variant (DV). In addition, the B-B-B group and C-C-B group showed reduced but existing protection against Omicron variant (OV). Moreover, A persistent rise in vMN titre against OV was observed 3 days after booster dose. Regarding safety, a heterologous prime-boost vaccine strategy is well tolerated. In this study, it was demonstrated that using vaccines of different platforms as booster dose can enhance protection against SARS-CoV-2 variants, offering potent neutralizing activity against wild-type virus (WT), Beta variant (BV), Delta variant (DV) and some protection against the Omicron variant (OV). In addition, a booster mRNA vaccine results in a more potent immune response than inactivated vaccine regardless of which platform was used for prime doses. |
format | Online Article Text |
id | pubmed-8877145 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88771452022-02-26 Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant Khong, Ka-Wa Liu, Danlei Leung, Ka-Yi Lu, Lu Lam, Hoi-Yan Chen, Linlei Chan, Pui-Chun Lam, Ho-Ming Xie, Xiaochun Zhang, Ruiqi Fan, Yujing To, Kelvin Kai-Wang Chen, Honglin Yuen, Kwok-Yung Chan, Kwok-Hung Hung, Ivan Fan-Ngai Vaccines (Basel) Article By vaccinating SARS-CoV-2 naïve individuals who have already received two doses of COVID-19 vaccines, we aimed to investigate whether a heterologous prime-boost strategy, using vaccines of different platforms as the booster dose, can enhance the immune response against SARS-CoV-2 virus variants. Participants were assigned into four groups, each receiving different combination of vaccinations: two doses of BNT162b2 followed by one dose of BNT162b2 booster (B-B-B); Combination of BNT162b2 (first dose) and CoronaVac (second dose) followed by one dose of BNT162b2 booster (B-C-B); two doses of CoronaVac followed by one dose of CoronaVac booster (C-C-C); two doses of CoronaVac followed by one dose of BNT162b2 booster (C-C-B). The neutralizing antibody in sera against the virus was determined with live virus microneutralization assay (vMN). The B-B-B group and C-C-B group demonstrated significantly higher immunogenicity against SARS-CoV-2 Wild type (WT), Beta variant (BV) and Delta variant (DV). In addition, the B-B-B group and C-C-B group showed reduced but existing protection against Omicron variant (OV). Moreover, A persistent rise in vMN titre against OV was observed 3 days after booster dose. Regarding safety, a heterologous prime-boost vaccine strategy is well tolerated. In this study, it was demonstrated that using vaccines of different platforms as booster dose can enhance protection against SARS-CoV-2 variants, offering potent neutralizing activity against wild-type virus (WT), Beta variant (BV), Delta variant (DV) and some protection against the Omicron variant (OV). In addition, a booster mRNA vaccine results in a more potent immune response than inactivated vaccine regardless of which platform was used for prime doses. MDPI 2022-01-21 /pmc/articles/PMC8877145/ /pubmed/35214619 http://dx.doi.org/10.3390/vaccines10020160 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Khong, Ka-Wa Liu, Danlei Leung, Ka-Yi Lu, Lu Lam, Hoi-Yan Chen, Linlei Chan, Pui-Chun Lam, Ho-Ming Xie, Xiaochun Zhang, Ruiqi Fan, Yujing To, Kelvin Kai-Wang Chen, Honglin Yuen, Kwok-Yung Chan, Kwok-Hung Hung, Ivan Fan-Ngai Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant |
title | Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant |
title_full | Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant |
title_fullStr | Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant |
title_full_unstemmed | Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant |
title_short | Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant |
title_sort | antibody response of combination of bnt162b2 and coronavac platforms of covid-19 vaccines against omicron variant |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877145/ https://www.ncbi.nlm.nih.gov/pubmed/35214619 http://dx.doi.org/10.3390/vaccines10020160 |
work_keys_str_mv | AT khongkawa antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT liudanlei antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT leungkayi antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT lulu antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT lamhoiyan antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT chenlinlei antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT chanpuichun antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT lamhoming antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT xiexiaochun antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT zhangruiqi antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT fanyujing antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT tokelvinkaiwang antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT chenhonglin antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT yuenkwokyung antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT chankwokhung antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant AT hungivanfanngai antibodyresponseofcombinationofbnt162b2andcoronavacplatformsofcovid19vaccinesagainstomicronvariant |